|
gptkbp:instanceOf
|
gptkb:monoclonal_antibody
|
|
gptkbp:administeredBy
|
subcutaneous injection
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2010
|
|
gptkbp:ATCCode
|
gptkb:M05BX04
|
|
gptkbp:brand
|
gptkb:Prolia
gptkb:Xgeva
|
|
gptkbp:CASNumber
|
gptkb:615258-40-7
|
|
gptkbp:contraindication
|
hypocalcemia
|
|
gptkbp:developedBy
|
gptkb:Amgen
|
|
gptkbp:discoveredBy
|
gptkb:Amgen
|
|
gptkbp:eliminationHalfLife
|
25 days
|
|
gptkbp:hasMolecularFormula
|
gptkb:C6400H9908N1720O1996S44
|
|
gptkbp:indication
|
prevention of skeletal-related events in cancer
treatment of bone loss in prostate cancer
treatment of postmenopausal osteoporosis
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits RANKL
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:routeOfAdministration
|
subcutaneous
|
|
gptkbp:sideEffect
|
gptkb:skin_infection
hypocalcemia
musculoskeletal pain
osteonecrosis of the jaw
|
|
gptkbp:target
|
gptkb:RANKL
|
|
gptkbp:UNII
|
4Y2E6FH3X6
|
|
gptkbp:usedFor
|
gptkb:bone
gptkb:giant_cell_tumor_of_bone
bone metastases
|
|
gptkbp:bfsParent
|
gptkb:Prolia
gptkb:Xgeva
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
denosumab
|